Innate And Adaptive Immune Engineering In Oncology

Innate and adaptive immune engineering in oncology uses genetic, cellular, and molecular design to redirect immune recognition, tumor killing, antigen presentation, and immune-memory formation. The field grew from adoptive cell transfer and cancer vaccines into engineered CAR-T cells, TCR-T cells, CAR-NK cells, CAR-macrophages, dendritic-cell vaccines, and innate immune agonists. Its importance comes from combining adaptive specificity with innate effector functions inside the tumor microenvironment^[1][2][3][4].

Mechanistically, adaptive immune engineering uses CARs to redirect T cells toward surface antigens and TCR engineering to recognize intracellular tumor peptides presented by MHC. CAR design links antigen-binding domains to CD3ζ and costimulatory signaling modules, enabling activation, proliferation, cytokine production, and cytotoxicity after antigen recognition. TCR-engineered T cells extend targeting to intracellular neoantigens, while personalized neoantigen vaccines stimulate tumor-specific T-cell responses through patient-specific mutation-derived antigens^[2][5][6][7].

Innate immune engineering broadens this strategy beyond T cells. CAR-NK cells combine natural cytotoxicity with engineered antigen recognition and showed clinical activity without major cytokine-release syndrome or neurotoxicity in early CD19-targeted lymphoma and leukemia testing. CAR-macrophages were engineered to direct phagocytosis against tumors, remodel the tumor microenvironment, and promote antigen presentation. Dendritic-cell immunotherapy uses antigen-loaded professional antigen-presenting cells, and sipuleucel-T improved overall survival in metastatic castration-resistant prostate cancer^[3][4][8][9].

Current applications include hematologic malignancies, solid tumors, neoantigen-driven precision therapy, macrophage-directed phagocytosis, NK-cell platforms, vaccine combinations, and innate-adaptor activation. Key gaps remain in antigen heterogeneity, immune escape, trafficking into solid tumors, suppressive myeloid and stromal barriers, manufacturing scalability, persistence, safety switches, and cytokine toxicity. Future research should integrate CAR/TCR engineering, Fc and phagocytosis checkpoints, dendritic-cell priming, STING or TLR activation, checkpoint blockade, and spatial tumor-immune profiling to coordinate innate and adaptive cancer immunity rather than treating them as separate therapeutic systems^{[1][3][4][6][7][8][9]}.